|Wednesday, May 23, 2018||
Click the diagram above
to view the XBL Navigator.
In vitro Drug-Drug Interaction (DDI) Services
"Drug interactions can result when one drug alters the pharmacokinetics of another drug or its metabolites" (FDA Guidance on Drug Interaction Studies, Feb. 2012). The FDA guidance recommends that "The study of drug-drug interaction for a new drug generally begins with in vitro studies to determine whether a drug is a substrate, inhibitor, or inducer of metabolizing enzymes". FDA and EMA (Guideline on the Investigation of Drug Interactions, June 2012) guidance's also outline a strategy for in vitro testing of transporter-mediated drug-drug interactions. WuXi/XBL provides a complete set of in vitro DDI studies as part of its comprehensive ADME/DMPK services.
In vitro DDI services include:
WuXi/XBL offers its DDI studies as either non-GLP or in compliance with GLP regulations
WuXi/XBL provides CYP services at both its locations (NJ; China) and provides transporter services in NJ in collaboration with Solvo® Biotechnology and thus offers fully integrated DDI services based on many years of experience.
|©2005-2017, XenoBiotic Laboratories, Inc. All rights reserved.
Website created by Princeton Internet Group (PING)